3 citations
,
December 2021 in “Dermatology reports” Dupilumab can improve both atopic dermatitis and alopecia universalis.
3 citations
,
November 2021 in “World Journal of Clinical Pediatrics” Vitamin D might help treat some types of hair loss, but more research is needed.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
2 citations
,
June 2020 in “Türkderm Türk deri hastalıkları ve frengi arşivi” Yellow dots and short vellus hairs are key signs for diagnosing alopecia areata using trichoscopy.
2 citations
,
June 2019 in “Serbian Journal of Dermatology and Venereology/Serbian Journal of Dermatology and Venerology” Platelet-rich plasma injections can effectively treat stubborn alopecia areata.
2 citations
,
June 2018 in “Journal of the American Academy of Dermatology” Alopecia areata causes varying hair loss and nail changes, and treatments include topical, systemic, and injectable therapies.
2 citations
,
July 2017 in “Skin appendage disorders” Alfredo Rebora suggests a simpler classification for hair loss and a new test for easier diagnosis.
1 citations
,
January 2025 in “American Journal of Translational Research” PPARα agonists may help treat alopecia areata by reducing inflammation.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Traditional treatment for pediatric alopecia areata is most effective and should be first choice.
1 citations
,
July 2023 in “Cutis” Scalp rolling might help regrow hair in people with a hair loss condition called Alopecia Areata.
1 citations
,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
1 citations
,
May 2023 in “The Journal of Dermatology” Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.
1 citations
,
January 2023 Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.
1 citations
,
September 2022 in “JMIR dermatology” Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.
1 citations
,
January 2020 in “Benha Journal of Applied Sciences” Certain gene variations may increase the risk and severity of alopecia areata.
1 citations
,
October 2013 in “Expert Review of Dermatology” Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.
1 citations
,
July 2012 in “Nasza Dermatologia Online” IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.
September 2025 in “Turkish Journal of Dermatology” Oxidative stress may play a role in alopecia areata, but depression and suicide risk are similar to healthy peers.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
January 2025 in “Advances in Dermatology and Allergology” The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.
April 2024 in “Bioscience trends” Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
January 2024 in “Dermatology practical & conceptual” Male gender and family history predict alopecia areata recurrence.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
December 2023 in “Research Square (Research Square)” These specific gene polymorphisms are not linked to Alopecia Areata in Egyptians.
Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.